EUVIMEDEUVIMED entdecken
Crossref

Evaluation of archived drug resistance mutations in HIV ‐1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID ‐19 pandemic

Aude Christelle Ka'e iD, Joseph Fokam iD, Willy Le Roi Togna Pabo, Aubin Nanfack, Ezechiel Ngoufack Jagni Semengue, Yagai Bouba, Alex Durand Nka, Suzie Tetang, Grace Beloumou, Desire Takou, Collins Chenwi iD, Michel Carlos Tommo Tchouaket und 11 weitere

HIV Medicine · 2023

DOI: 10.1111/hiv.13459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2023. Verfasst von Aude Christelle Ka'e und 22 weiteren Autor:innen. Beteiligte Einrichtung: Chantal Biya International Reference Centre (CIRCB), Yaounde, Cameroon. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, COVID-19, HIV Seropositivity. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With the success of antiretroviral therapy (ART), children born with HIV are more likely to reach adolescence. However, frequent non‐adherence to ART in adolescents living with HIV (ALHIV) leads to viral replication. Notably, a viraemic infection might lead to archived drug resistance mutations (ADRMs). Hence, within the context of the COVID‐19 pandemic, we aimed to compare the patterns of ADRMs in viraemic and non‐viraemic vertically infected ALHIV and to assess their immunity to and diagnosis of SARS‐CoV‐2.

Methods

A comparative study was conducted among COVID‐19‐unvaccinated ALHIV receiving ART in Yaoundé‐Cameroon over the period October 2021 to March 2022. Plasma HIV‐RNA was measured using Abbott® m2000rt ; HIV‐1 genotyping was performed on buffy‐coat (HIV‐1 DNA) and ADRMs were interpreted using HIVdb.v9.0.1. Patterns of HIV‐1 ADRMs were compared between viraemic (≥ 1.60 log 10 HIV‐1 RNA copies/ml) and non‐viraemic (< 1.60 log 10 copies/ml) individuals. SARS‐CoV‐2 antibodies were assessed on whole blood using Abbott Panbio COVID‐19 immunoglobulin G/M (IgG/IgM) rapid test and COVID‐19 polymerase chain reaction test was performed using nasopharyngeal swab samples.

Results

Of the 60 ALHIV [aged 17 (16–19) years, 51.6% female], median ART duration was 14 (12–16) years; 31/55 (56.3%) were exposed to nonnucleoside reverse transcriptase inhibitor (NNRTI)‐based first‐line ART (of whom 19/31 transitioned to dolutegravir‐based ART in 2020) and 24/55 (43.6%) were on second‐line ART. Forty‐two out of 60 (70.0%) ALHIV were non‐viraemic; 43/60 (71.6%) were successfully sequenced. Overall the ADRM rate was 62.7% (27/43), with 69.2% (9/13) viraemic and 60.0% (18/30) non‐viraemic ( p = 0.56). NNRTI‐ADRMs were significantly higher among viraemic ALHIV (69.2% vs. 46.7%, p = 0.030). Regarding immunity, those with CD4 nadir < 350 cells/μl had significantly higher rates of ADRMs [adjusted odds ratio (aOR) = 3.20 (1.36–95.53), p = 0.03]. In relation to COVID‐19 immunity, overall SARS‐CoV‐2 IgG seropositivity was 28.3% (17/60), whereas 0% (0/60) were seropositive to IgM; in particular, those with CD4 count nadir ≥ 350 cells/μl had higher odds of SARS‐CoV‐2 IgG seropositivity [OR =7.85 (2.03–30.28), p < 0.01]. No significant association was found between SARS‐CoV‐2 IgG seropositivity and HIV‐RNA (non‐viraemic, 33.3%; viraemic, 16.7%; p = 0.18). SARS‐CoV‐2 RNA prevalence was 4.5% (2/44). The two positive participants were with low‐levels of viral load (Ct > 30) and seropositive to IgG.

Conclusion

In the context of virological success, the majority of ALHIV harbour ADRMs, essentially driven by NNRTI mutations and low CD4 nadir. During the current pandemic, about one‐third of ALHIV were previously exposed to SARS‐CoV‐2. However, some children might have been exposed and uninfected and others might have been infected but showed no serological response at sampling. These findings support the use of NNRTI‐sparing regimens and the implementation of COVID‐19 barrier measures targeting ALHIV during such a pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsCOVID-19HIV SeropositivityAnti-HIV AgentsChildHumansFemaleAdolescentMalePandemicsRNA, ViralCameroonDrug Resistance, ViralSARS-CoV-2Anti-Retroviral AgentsReverse Transcriptase InhibitorsMutationDNAViral Load

Stichwörter der Autor:innen

CD4 nadirHIVSARS-CoV-2 antibodiesadolescentsarchived drug resistance mutations

Substanzen

RNA, ViralAnti-Retroviral AgentsReverse Transcriptase InhibitorsDNAAnti-HIV Agents

Autor:innen und Institutionen

  • Chantal Biya International Reference Centre (CIRCB), Yaounde, Cameroon.
  • PhD Courses in Microbiology, Immunology, Infectious Diseases and Transplants (MIMIT), University of Rome "Tor Vergata", Rome, Italy.
  • Faculty of Science University of Buea, University of Yaounde I, Geneva, Switzerland.
  • Faculty of Medecine and Biomedical Science, University of Yaounde I, Geneva, Switzerland.
  • IAS Research Cure Academy, Geneva, Switzerland.
  • National Public Health Emergencies Operations Coordination Centre, Ministry of Public Health, Yaounde, Cameroon.

ORCID-Profile: Aude Christelle Ka'e, Joseph Fokam, Collins Chenwi, John O Otshudiema, Maria M Santoro

Förderung

  • World Health Organization

Zitieren

APA

Ka'e, A. C., Fokam, J., Togna Pabo, W. L. R., Nanfack, A., Ngoufack Jagni Semengue, E., Bouba, Y., Nka, A. D., Tetang, S., Beloumou, G., Takou, D., Chenwi, C., Tommo Tchouaket, M. C., Abba, A., Djupsa, S., Sosso, S. M., Pamen, N. B., Otshudiema, J. O., Boum, Y., Colizzi, V., …, & Santoro, M. M. (2023). Evaluation of archived drug resistance mutations in HIV ‐1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID ‐19 pandemic. HIV Medicine. https://doi.org/10.1111/hiv.13459

Vancouver

Ka'e AC, Fokam J, Togna Pabo WLR, Nanfack A, Ngoufack Jagni Semengue E, Bouba Y, et al. Evaluation of archived drug resistance mutations in HIV ‐1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID ‐19 pandemic. HIV Medicine. 2023. doi:10.1111/hiv.13459

BibTeX
@article{Kae2023,
  author = {Ka'e, Aude Christelle and Fokam, Joseph and Togna Pabo, Willy Le Roi and Nanfack, Aubin and Ngoufack Jagni Semengue, Ezechiel and Bouba, Yagai and Nka, Alex Durand and Tetang, Suzie and Beloumou, Grace and Takou, Desire and Chenwi, Collins and Tommo Tchouaket, Michel Carlos and Abba, Aissatou and Djupsa, Sandrine and Sosso, Samuel Martin and Pamen, Nounouce Bouba and Otshudiema, John O and Boum, Yap and Colizzi, Vittorio and Ndjolo, Alexis and Perno, Carlo-Federico and Ceccherini-Silberstein, Francesca and Santoro, Maria M},
  title = {Evaluation of archived drug resistance mutations in HIV ‐1 DNA among vertically infected adolescents under antiretroviral treatment in Cameroon: Findings during the COVID ‐19 pandemic},
  journal = {HIV Medicine},
  year = {2023},
  doi = {10.1111/hiv.13459}
}
Kostenlos starten →